In silico analysis identifies novel inhibitors targeting GABA transporter 1, suggesting new drug candidates.
γ-Aminobutyric acid (GABA) targets are relevant in drug discovery because modulation of its levels can be used in the treatment of various diseases, such as epilepsy, anxiety and depression. Using a combined in silico approach, we focused on GABA transporter 1 to select new inhibitors from the ZINC database. A set of known inhibitors was used as a reference. Our results propose several compounds as potential new ligands.
No takes yet. Share an insight, caveat, or question.
Stevanović et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: